Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amphotericin B cholesterol sulfate complex for secondary prophylaxis of invasive fungal disease after allogeneic hematopoietic stem cell transplantation
ChiCTR2300067279Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jan 2023
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amphotericin B lipid complex in invasive mycoses, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Occurrence rate of breakthrough fungal infection and recurrence rate of original fungal infection. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
amphotericin B lipid complex
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on ChiCTR2300067279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067279.